Skip to main content

Table 2 SIRT2 deletion versus clinicopathological outcomes in the prostate cancer TCGA database (n = 499)

From: Dysregulation of Sirtuin 2 (SIRT2) and histone H3K18 acetylation pathways associates with adverse prostate cancer outcomes

  SIRT2 Deleted (n = 30) SIRT2 Diploid (n = 452) P
Age (Median/IQR) 64(61.75–66.75) 61(56–66)  
TNM stage
 T1 0 2(0.4%)  
 T2 5(16.67%) 164(40.2%)  
 T3 22(73.34%) 276(61.2%)  
 T4 3(10%) 9(2%) 0.01 a
 N1 8(27%) 79(17.4%) 0.22
 M+   3  
Recurrence
 Yes 10(33.34%) 81(17.9%)  
 No 15(50%) 290(64%) 0.04 a
Bilateral 29(96%) 435(96%) 1
LNDa dissection 29(96%) 421(90%) 0.7
Nodes (Median/IQR) 7(4–16) 9(5–16)  
Positive margins 16(53%) 152(33.6%) 0.04 a
Complete remission 9 (30%) 164(33.6%) 0.8
Partial remission 4 (13%) 29(6.4%) 0.14
Biochemical relapse 3 (20%) 48(10.6%) 0.13
  1. aClinicopathological outcomes were compared between patients with diploid and deleted SIRT2. Patients with SIRT2 deletion had higher clinical ‘T’ stage, increased chance of recurrence and greater odds of positive surgical margins